ASCO Guideline Update | Chemotherapy and targeted therapy for human epidermal growth factor receptor 2–negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor–negative. 17 Aug, 2022 | 14:17h | UTC Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology